Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the incidence of Graft vs. Host Disease (GVHD)
after non-myeloablative transplantation can be reduced by using a combination of three immune
suppressive medication; sirolimus, tacrolimus and methotrexate.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital